Marching in again? Latest Xtandi petition raises questions on if NIH has changed its tune
The NIH is expected to decide sometime this month on whether it wants to step in and offer cheaper versions of Astellas’ prostate cancer drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
